🔎 Trials Near Me

Beranda › Karsinoma Sel Skuamosa › Virginia

Uji klinis Karsinoma Sel Skuamosa di Virginia

6 studi untuk Karsinoma Sel Skuamosa mencari peserta di lokasi di Virginia.

Kota di Virginia

Teks studi resmi (Bahasa Inggris)

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  • University of Virginia, Charlottesville
  • Macon Joan Brock Virginia Health Sciences Eastern Virginia Medical Group at Old Dominion University, Norfolk
Menerima pesertaFase 3
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04892173

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  • USO-Virginia Cancer Specialists, PC, Fairfax
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06561685

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

  • Inova Schar Cancer Center, Fairfax
Menerima pesertaFase 2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT04915183

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

  • Research Site, Fairfax
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07115043

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

  • VCU Massey Cancer Center, Richmond
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06064877

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

  • Virginia Cancer Specialists, Fairfax
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT04370587

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.